Xenagos Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2026-05-15.
Xenagos Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 15, 2026. The filing reports $2.52M sold. Its industry group is Biotechnology. It names Michael McElhaugh (Executive Officer, Director), Abel De La Rosa (Director), Patrick Higgins (Director) (SEC Form D, May 15, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Xenagos Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-05-15 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Xenagos Bio, Inc.
Free to see. No signup.
More on the people and the money behind Xenagos Bio, Inc., from the filings we hold.
Biotechnology raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.
Get an email when Xenagos Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Xenagos Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Xenagos Bio, Inc. →Get the full cited report on Xenagos Bio, Inc.
What the filing shows about Xenagos Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Xenagos Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Xenagos Bio, Inc.'s address as 121 S. Broad St., 15TH Floor, #1015, Philadelphia, PA 19107.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Xenagos Bio, Inc. is a registered filer with the SEC (CIK 2134608) and has filed since 2026-05-15. 1 filing is on record, the latest on 2026-05-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Xenagos Bio, Inc.'s Form D of 2026-05-15 names Michael McElhaugh, Abel De La Rosa and Patrick Higgins as its officers, directors or promoters.
Its new offerings report $2.52M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $2.52M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Michael McElhaugh is named as Executive Officer and Director on the Form D that Xenagos Bio, Inc. filed with the SEC on 15 May 2026, one of 3 people that filing names.
Abel De La Rosa is named as Director on the Form D that Xenagos Bio, Inc. filed with the SEC on 15 May 2026, one of 3 people that filing names.
Patrick Higgins is named as Director on the Form D that Xenagos Bio, Inc. filed with the SEC on 15 May 2026, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2026-05-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Xenagos Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Xenagos Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Xenagos Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Xenagos Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Xenagos Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Xenagos Bio, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Philadelphia
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/xenagos-bio-inc-form-d-26000001